Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H14O3 |
Molecular Weight | 242.2699 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=CC=C(C=C1)[C@H]2COC3=CC(O)=CC=C3C2
InChI
InChIKey=ADFCQWZHKCXPAJ-GFCCVEGCSA-N
InChI=1S/C15H14O3/c16-13-4-1-10(2-5-13)12-7-11-3-6-14(17)8-15(11)18-9-12/h1-6,8,12,16-17H,7,9H2/t12-/m1/s1
Molecular Formula | C15H14O3 |
Molecular Weight | 242.2699 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15883431
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/15883431
EQUOL, (-)- is the (S)-enantiomer of the naturally-occurring isoflavandiol estrogen, equol. EQUOL, (-)- (US-131), is a first-in-class, nonsteroidal, nonhormonal, small molecule (S-equol) that has higher selectivity toward estrogen receptor β (ERβ) than to estrogen receptor α (ERα). S-equol is the exclusive product of human intestinal bacterial synthesis from soy isoflavones. Two-Phase 1 studies have seen completed and published; AUS-131 was safe and well-tolerated in humans. A Phase 2a trial in menopausal women with vasomotor symptoms (VMS) has recently been completed (169 patients). A second Phase 2a trial in men with benign prostatic hyperplasia (BPH) is on track.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15883431 |
0.73 nM [Ki] | ||
Target ID: CHEMBL390 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26638886 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4953 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19776178 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
EQUOL, (-)- plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
1907 nM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19776178 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
EQUOL, (-)- plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
25299 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19776178 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
EQUOL, (-)- plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
8584 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19776178 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
EQUOL, (-)- plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19776178 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
EQUOL, (-)- plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
7.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19776178 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
EQUOL, (-)- plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
The production of S-equol from daidzein is associated with a cluster of three genes in Eggerthella sp. YY7918. | 2016 |
|
Phytoestrogen Metabolism by Adult Human Gut Microbiota. | 2016 Aug 9 |
|
Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer. | 2016 Jul 5 |
Patents
Sample Use Guides
The following doses have been studied in scientific research:
BY MOUTH:
For menopausal symptoms such as hot flashes: 10-40 mg per day in divided doses.
For preventing weak bones (osteoporosis): 10 mg per day.
For reducing skin wrinkles: 5 or 15 mg two times per day.
For metabolic syndrome: 10 mg per day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16898868
S-equol (EQUOL, (-)-) inhibited the growth of the breast cancer cell line MDA-MB-231 (> or = 10 uM) and the prostate cancer cell lines LNCaP (> or = 5 uM) and LAPC-4 (> or = 2.5 uM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:19:57 GMT 2023
by
admin
on
Fri Dec 15 17:19:57 GMT 2023
|
Record UNII |
2T6D2HPX7Q
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2182
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID0022309
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
2T6D2HPX7Q
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
2T6D2HPX7Q
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
300000025997
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
531-95-3
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
1803717
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
m4971
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL198877
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
DB11674
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
C120313
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
Equol
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
91469
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY | |||
|
208-522-2
Created by
admin on Fri Dec 15 17:19:57 GMT 2023 , Edited by admin on Fri Dec 15 17:19:57 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
BINDING
Ki
|
||
|
TARGET -> AGONIST |
EC50
|
||
|
TARGET -> AGONIST |
Ki
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE ACTIVE |
Produced by intestinal microbiota. Similar activity as estrodiol
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |